FDA Approves First Drug Targeting "Undruggable" Kras Protein in Pancreatic Cancer

The FDA approved daraxonrasib (Rasonque) on August 26, 2026, the first targeted therapy for metastatic pancreatic cancer. In a 500-patient company-funded trial, median survival reached 13.2 months versus 6.7 months for chemotherapy. The drug blocks a Kras mutation — long considered "undruggable" — that drives over 90% of pancreatic cancer cases. Pancreatic cancer's five-year survival rate is 13%. The trial enrolled only previously treated patients, and the company-funded design warrants independent confirmation.